Scolaris Content Display Scolaris Content Display

Related content

Jump to:

Related reviews and protocols

Topics

Topics

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figures and Tables -
Figure 1

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Navigate to figure in ReviewOpen in new tab

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figures and Tables -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Navigate to figure in ReviewOpen in new tab

Forest plot of comparison: 1 Lycopene versus control, outcome: 1.2 PSA levels (ng/mL).
Figures and Tables -
Figure 3

Forest plot of comparison: 1 Lycopene versus control, outcome: 1.2 PSA levels (ng/mL).

Navigate to figure in ReviewOpen in new tab

Comparison 1 Lycopene versus control, Outcome 1 Incidence of prostate cancer.
Figures and Tables -
Analysis 1.1

Comparison 1 Lycopene versus control, Outcome 1 Incidence of prostate cancer.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Lycopene versus control, Outcome 2 PSA levels (ng/mL).
Figures and Tables -
Analysis 1.2

Comparison 1 Lycopene versus control, Outcome 2 PSA levels (ng/mL).

Navigate to figure in ReviewOpen in new tab

Comparison 1 Lycopene versus control, Outcome 3 Decrease in PSA levels.
Figures and Tables -
Analysis 1.3

Comparison 1 Lycopene versus control, Outcome 3 Decrease in PSA levels.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Lycopene versus control, Outcome 4 Increase in PSA levels.
Figures and Tables -
Analysis 1.4

Comparison 1 Lycopene versus control, Outcome 4 Increase in PSA levels.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Lycopene versus control, Outcome 5 Prostate symptom score (IPSS).
Figures and Tables -
Analysis 1.5

Comparison 1 Lycopene versus control, Outcome 5 Prostate symptom score (IPSS).

Navigate to figure in ReviewOpen in new tab

Comparison 1 Lycopene versus control, Outcome 6 Incidence of Benign Prostatic Hyperplasia.
Figures and Tables -
Analysis 1.6

Comparison 1 Lycopene versus control, Outcome 6 Incidence of Benign Prostatic Hyperplasia.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Lycopene versus control, Outcome 7 Lycopene levels (µg/mL).
Figures and Tables -
Analysis 1.7

Comparison 1 Lycopene versus control, Outcome 7 Lycopene levels (µg/mL).

Navigate to figure in ReviewOpen in new tab
Comparison 1. Lycopene versus control

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of prostate cancer Show forest plot

1

40

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.08, 1.46]

2 PSA levels (ng/mL) Show forest plot

2

114

Mean Difference (IV, Fixed, 95% CI)

‐0.34 [‐2.01, 1.32]

3 Decrease in PSA levels Show forest plot

1

77

Risk Ratio (M‐H, Fixed, 95% CI)

1.03 [0.32, 3.26]

4 Increase in PSA levels Show forest plot

1

40

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.29, 1.52]

5 Prostate symptom score (IPSS) Show forest plot

1

37

Mean Difference (IV, Fixed, 95% CI)

0.20 [‐2.66, 3.06]

6 Incidence of Benign Prostatic Hyperplasia Show forest plot

1

40

Risk Ratio (M‐H, Fixed, 95% CI)

1.33 [0.34, 5.21]

7 Lycopene levels (µg/mL) Show forest plot

2

114

Mean Difference (IV, Random, 95% CI)

0.39 [‐0.19, 0.98]
Figures and Tables -
Comparison 1. Lycopene versus control
Navigate to table in Review